Trials / Conditions / Deleterious BRCA2 Gene Mutation
Deleterious BRCA2 Gene Mutation
6 registered clinical trials studyying Deleterious BRCA2 Gene Mutation.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Withdrawn | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer NCT03432676 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fall NCT03586661 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NCT03845296 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Pa NCT03546972 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations NCT02760849 | M.D. Anderson Cancer Center | N/A |
| Completed | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer NCT02282345 | M.D. Anderson Cancer Center | Phase 2 |